Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Wiltrout Website

Robert H. Wiltrout, Ph.D.

Selected Publications

1)  Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH.
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Proc. Natl. Acad. Sci. U.S.A. 106: 19455-60, 2009.
2)  Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH.
Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.
J. Exp. Med. 207: 2455-67, 2010.
3)  Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.
Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors.
Cancer Res. 71: 2718-27, 2011.
4)  Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, Back T, Song N, Datla M, Sun Z, Goldszmid R, Lin F, Cohoon T, Pike K, Wu X, Schrump DS, Wong K, Young HA, Trinchieri G, Wiltrout RH, Hu Y.
The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas.
Cancer Cell. 23: 527-40, 2013.
5)  Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.
Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy.
J. Immunol. 192: 5821-29, 2014.
6)  Weiss JM, Gregory Alvord W, Quiñones OA, Stauffer JK, Wiltrout RH.
CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.
Hum. Immunol. 75: 614-20, 2014.
7)  Ortaldo JR, Wiltrout RH, Reynolds CW.
Natural killer activity: early days, advances, and seminal observations.
Crit Rev Oncog. 19: 1-13, 2014.
8)  Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, Wilkins DE, Alderson KL, Hsiao HH, Weiss JM, Monjazeb AM, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltrout RH, Redelman D, Taub DD, Murphy WJ.
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy.
J. Exp. Med. 210: 2223-37, 2013.
9)  Jiang Q, Weiss JM, Wiltrout RH.
A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment.
Oncoimmunology. 1: 115-117, 2012.
10)  Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH.
Chronic inflammation, immune escape and oncogenesis in the liver: A unique neighborhood for novel intersections.
Hepatology. 56: 1567-74, 2012.
11)  Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.
Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy.
Blood. 119: 3073-83, 2012.
12)  Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Perwez Hussain S, Harris CC.
NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
Int J Cancer. 132: 9-18, 2012.
13)  Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.
Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.
PLoS ONE. 7: e33303, 2012.
14)  Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, Murphy WJ.
Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation.
Biol. Blood Marrow Transplant. 17: 1754-64, 2011.
15)  Chan T, Wiltrout RH, Weiss JM.
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.
Int Immunopharmacol. 11: 879-89, 2011.
16)  Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, Wiltrout RH.
mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment.
Cancer Res. 71: 4074-84, 2011.
17)  Subleski JJ, Hall VL, Wolfe TB, Scarzello AJ, Weiss JM, Chan T, Hodge DL, Back TC, Ortaldo JR, Wiltrout RH.
TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.
J. Immunol. 186: 838-47, 2011.
18)  Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH.
The split personality of NKT cells in malignancy, autoimmune and allergic disorders.
Immunotherapy. 3: 1167-84, 2011.
19)  Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ.
Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood.
Eur. J. Immunol. 40: 1099-106, 2010.
20)  Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ.
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
Cancer Res. 69: 6615-23, 2009.
21)  Subleski JJ, Wiltrout RH, Weiss JM.
Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.
J. Autoimmun. 33: 275-81, 2009.
22)  Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
J. Clin. Oncol. 27: 2705-11, 2009.
23)  Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Designing phase 0 cancer clinical trials.
Clin. Cancer Res. 14: 3675-82, 2008.
24)  Hussain SP, He P, Subleski J, Hofseth LJ, Trivers GE, Mechanic L, Hofseth AB, Bernard M, Schwank J, Nguyen G, Mathe E, Djurickovic D, Haines D, Weiss J, Back T, Gruys E, Laubach VE, Wiltrout RH, Harris CC.
Nitric oxide is a key component in inflammation-accelerated tumorigenesis.
Cancer Res. 68: 7130-6, 2008.
25)  Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials: conceptions and misconceptions.
Cancer J. 14: 133-7, 2008.
26)  Alderson KL, Zhou Q, Berner V, Wilkins DE, Weiss JM, Blazar BR, Welniak LA, Wiltrout RH, Redelman D, Murphy WJ.
Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy.
J. Immunol. 180: 2981-8, 2008.
27)  Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW.
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Clin. Cancer Res. 13: 1936-46, 2007.
28)  Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.
Compressing drug development timelines in oncology using phase '0' trials.
Nat. Rev. Cancer. 7: 131-9, 2007.
29)  Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ.
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
Nat. Med. 13: 354-60, 2007.
30)  Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH.
Immunotherapy of cancer by IL-12-based cytokine combinations.
Expert Opin Biol Ther. 7: 1705-21, 2007.
31)  Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Mol. Interv. 7: 325-34, 2007.
32)  Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH.
The CD95 receptor: apoptosis revisited.
Cell. 129: 447-50, 2007.
33)  Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH.
Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.
Cancer Res. 66: 11005-12, 2006.
34)  Yazawa H, Murakami T, Li HM, Back T, Kurosaka K, Suzuki Y, Shorts L, Akiyama Y, Maruyama K, Parsoneault E, Wiltrout RH, Watanabe M.
Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Cancer Gene Ther. 13: 993-1001, 2006.
35)  Shorts L, Weiss JM, Lee JK, Welniak LA, Subleski J, Back T, Murphy WJ, Wiltrout RH.
Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
J. Immunol. 176: 6543-52, 2006.
36)  Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH.
Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.
Cell. Immunol. 235: 145-52, 2005.
37)  Ortaldo JR, Winkler-Pickett RT, Bere EW, Watanabe M, Murphy WJ, Wiltrout RH.
In Vivo Hydrodynamic Delivery of cDNA Encoding IL-2: Rapid, Sustained Redistribution, Activation of Mouse NK Cells, and Therapeutic Potential in the Absence of NKT Cells.
J Immunol. 175: 693-9, 2005.
38)  Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW, Murphy WJ, Wiltrout RH.
Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
J Immunol. 172: 943-53, 2004.
39)  Gamero AM, Young HA, Wiltrout RH.
Inactivation of Stat3 in tumor cells; Releasing a brake on immune responses against cancer?.
Cancer Cell. 5: 111-2, 2004.
40)  Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, Haines D, Laubach VE, Wiltrout RH, Djurickovic D, Harris CC.
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.
Cancer Research. 64: 6849-53, 2004.
41)  Welniak LA, Shorts L, Subleski J, Blazar BR, Wiltrout RH, Murphy WJ.
Tumor regression by anti-CD40 and interleukin-2: Role of CD40 on hematopoietic cells and organ-specific effects.
Biol Blood and Bone Marrow Transp. 10: 534-539, 2004.
42)  Cataisson C, Joseloff E, Murillas R, Wang A, Atwell C, Torgerson S, Gerdes M, Subleski J, Gao JL, Murphy PM, Wiltrout RH, Vinson C, Yuspa SH.
Activation of cutaneous protein kinase Calpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways.
J Immunol. 171: 2703-13, 2003.
43)  Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH.
Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.
Apoptosis. 8: 151-60, 2003.
44)  Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH.
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
J Immunol. 170: 2727-33, 2003.
45)  Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ.
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Cancer Res. 63: 207-13, 2003.
46)  Hixon JA, Anver MR, Blazar BR, Panoskaltsis-Mortari A, Wiltrout RH, Murphy WJ.
Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut.
Biol. Blood Marrow Transplant. 8: 316-25, 2002.
47)  Akiyama Y, Maruyama K, Nara N, Hojo T, Cheng JY, Mori T, Wiltrout RH, Yamaguchi K.
Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters.
Cancer Lett. 184: 37-47, 2002.
48)  Wigginton JM, Wiltrout RH.
IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside.
Expert Opin Biol Ther. 2: 513-24, 2002.
49)  Wigginton JM, Lee JK, Wiltrout TA, Alvord WG, Hixon JA, Subleski J, Back TC, Wiltrout RH.
Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2.
J Immunol. 169: 4467-74, 2002.
50)  Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
J Immunol. 168: 3484-92, 2002.
51)  Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ.
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation.
Biol. Blood Marrow Transplant. 7: 136-43, 2001.
52)  Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrout RH.
Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
J Immunol. 166: 1156-68, 2001.
53)  Welniak LA, Khaled AR, Anver MR, Komschlies KL, Wiltrout RH, Durum S, Ruscetti FR, Blazar BR, Murphy WJ.
Gastrointestinal cells of IL-7 receptor null mice exhibit increased sensitivity to irradiation.
J. Immunol. 166: 2924-8, 2001.
54)  Lee JK, Back TC, Komschlies KL, Ruscetti FW, Young HA, Wiltrout RH.
Hematopoietic switch from lymphoid to granulocytic development in 3LL tumor-bearing mice.
In Vivo. 15: 255-63, 2001.
55)  Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH.
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
J Clin Invest. 108: 51-62, 2001.
56)  Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH.
Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.
Cancer Res. 61: 6255-63, 2001.
57)  Park JW, Gruys ME, McCormick K, Lee JK, Subleski J, Wigginton JM, Fenton RG, Wang JM, Wiltrout RH.
Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).
J Immunol. 166: 3763-70, 2001.
58)  Welniak LA, Blazar BR, Wiltrout RH, Anver MR, Murphy WJ.
Role of interleukin-12 in acute graft-versus-host disease(1).
Transplant. Proc. 33: 1752-3, 2001.
59)  Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
J Exp Med. 193: 661-70, 2001.
60)  Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K.
Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Gene Ther. 7: 2113-21, 2000.
61)  Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Wiltrout RH.
IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.
J Immunol. 164: 231-9, 2000.
62)  Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA.
In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells.
Eur. J. Immunol. 30: 1998-2006, 2000.
63)  Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ.
Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning.
Biol. Blood Marrow Transplant. 6: 604-12, 2000.
64)  Wiltrout RH.
Regulation and antimetastatic functions of liver-associated natural killer cells.
Immunol Rev. 174: 63-76, 2000.
65)  Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C.
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Oncogene. 19: 1020-7, 2000.
66)  Hoshino T, Wiltrout RH, Young HA.
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response.
J. Immunol. 162: 5070-7, 1999.
67)  Watanabe M, Fenton RG, Wigginton JM, McCormick KL, Volker KM, Fogler WE, Roessler PG, Wiltrout RH.
Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.
J. Immunol. 163: 1943-50, 1999.
68)  Ito D, Back TC, Shakhov AN, Wiltrout RH, Nedospasov SA.
Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment.
J. Immunol. 163: 2809-15, 1999.
69)  Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR.
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
J. Clin. Invest. 102: 1742-8, 1998.
70)  Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH.
Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
J. Immunol. 161: 3957-65, 1998.
71)  Fogler WE, Volker K, Watanabe M, Wigginton JM, Roessler P, Brunda MJ, Ortaldo JR, Wiltrout RH.
Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.
J. Immunol. 161: 6014-21, 1998.
72)  Siders WM, Wright PW, Hixon JA, Alvord WG, Back TC, Wiltrout RH, Fenton RG.
T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
J. Immunol. 160: 5465-74, 1998.
73)  Watanabe M, McCormick KL, Volker K, Ortaldo JR, Wigginton JM, Brunda MJ, Wiltrout RH, Fogler WE.
Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.
Am. J. Pathol. 150: 1869-80, 1997.
74)  Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W, Belldegrun A.
Renal cell carcinoma: recent progress and future directions.
Cancer Res. 57: 5189-95, 1997.
75)  Brown NJ, Ali S, Reed MW, Wiltrout R, Rees RC.
Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Br. J. Cancer. 76: 1572-8, 1997.
76)  Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH.
Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.
J. Natl. Cancer Inst. 88: 38-43, 1996.
77)  Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV.
Antitumor activity of interleukin 12 in preclinical models.
Cancer Chemother. Pharmacol. 38 Suppl: S16-21, 1996.
78)  Usui N, Matsushima K, Pilaro AM, Longo DL, Wiltrout RH.
Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
Biotherapy. 9: 199-208, 1996.
79)  Sayers TJ, Lloyd AR, McVicar DW, O'Connor MD, Kelly JM, Carter CR, Wiltrout TA, Wiltrout RH, Smyth MJ.
Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3.
J. Leukoc. Biol. 59: 763-8, 1996.
80)  Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH.
Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination.
Ann. N. Y. Acad. Sci. 795: 434-9, 1996.
81)  Carter CR, Sayers TJ, Wiltrout RH, Turcovski-Corrales SM, Taub DD.
Generation of antigenic peptides by lymphocyte granule serine proteases (granzymes).
Cell. Immunol. 172: 235-45, 1996.
82)  Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW.
Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2.
Cancer Res. 56: 1131-6, 1996.
83)  Brunda MJ, Luistro L, Rumennik L, Wright RB, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV.
Interleukin-12: murine models of a potent antitumor agent.
Ann. N. Y. Acad. Sci. 795: 266-74, 1996.
84)  Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, Wiltrout RH.
NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction.
J. Immunol. 156: 4707-14, 1996.
85)  Grzegorzewski KJ, Komschlies KL, Franco JL, Ruscetti FW, Keller JR, Wiltrout RH.
Quantitative and cell-cycle differences in progenitor cells mobilized by recombinant human interleukin-7 and recombinant human granulocyte colony-stimulating factor.
Blood. 88: 4139-48, 1996.
86)  Holmund JT, Kopp WC, Wiltrout RH, Longo DL, Urba WJ, Janik JE, Sznol M, Conlon KC, Fenton RG, Hornung R.
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.
J. Natl. Cancer Inst. 87: 134-6, 1995.
87)  Wiltrout RH, Gregorio TA, Fenton RG, Longo DL, Ghosh P, Murphy WJ, Komschlies KL.
Cellular and molecular studies in the treatment of murine renal cancer.
Semin. Oncol. 22: 9-16, 1995.
88)  Komschlies KL, Grzegorzewski KJ, Wiltrout RH.
Diverse immunological and hematological effects of interleukin 7: implications for clinical application.
J. Leukoc. Biol. 58: 623-33, 1995.
89)  Fogler WE, Pearson JW, Volker K, Ariyoshi K, Watabe H, Riggs CW, Wiltrout RH, Longo DL.
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
J. Natl. Cancer Inst. 87: 94-104, 1995.
90)  Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC.
Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.
J. Natl. Cancer Inst. 87: 1478-83, 1995.
91)  Grzegorzewski KJ, Komschlies KL, Jacobsen SE, Ruscetti FW, Keller JR, Wiltrout RH.
Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7.
J. Exp. Med. 181: 369-74, 1995.
92)  Franco JL, Ghosh P, Wiltrout RH, Carter CR, Zea AH, Momozaki N, Ochoa AC, Longo DL, Sayers TJ, Komschlies KL.
Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.
Cancer Res. 55: 3840-6, 1995.
93)  Boerman OC, Gregorio TA, Grzegorzewski KJ, Faltynek CR, Kenny JJ, Wiltrout RH, Komschlies KL.
Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants.
J. Leukoc. Biol. 58: 151-8, 1995.
94)  MacPhee MJ, Wiltrout RH, McCormick KL, Sayers TJ, Pilaro AM.
A method for obtaining and culturing large numbers of purified organ-derived murine endothelial cells.
J. Leukoc. Biol. 55: 467-75, 1994.
95)  Komschlies KL, Gregorio TA, Gruys ME, Back TC, Faltynek CR, Wiltrout RH.
Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
J. Immunol. 152: 5776-84, 1994.
96)  Grzegorzewski K, Komschlies KL, Mori M, Kaneda K, Usui N, Faltynek CR, Keller JR, Ruscetti FW, Wiltrout RH.
Administration of recombinant human interleukin-7 to mice induces the exportation of myeloid progenitor cells from the bone marrow to peripheral sites.
Blood. 83: 377-85, 1994.
97)  Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL.
Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy.
Cancer Res. 54: 2969-72, 1994.
98)  Komschlies KL, Back TT, Gregorio TA, Gruys ME, Damia G, Wiltrout RH, Faltynek CR.
Effects of rhIL-7 on leukocyte subsets in mice: implications for antitumor activity.
Immunol. Ser. 61: 95-104, 1994.
99)  Kaneda K, Pilaro AM, Sayers TJ, Nagashima K, Gonda MA, Ortaldo JR, Wiltrout RH.
Quantitative analysis of rod-cored vesicles and dense granules of large granular lymphocytes in the liver, spleen, and peripheral blood of rats.
Cell Tissue Res. 276: 187-95, 1994.
100)  Grzegorzewski K, Ruscetti FW, Usui N, Damia G, Longo DL, Carlino JA, Keller JR, Wiltrout RH.
Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin.
J. Exp. Med. 180: 1047-57, 1994.
101)  Pilaro AM, Taub DD, McCormick KL, Williams HM, Sayers TJ, Fogler WE, Wiltrout RH.
TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma.
J. Immunol. 153: 333-42, 1994.
102)  Murphy WJ, Back TC, Conlon KC, Komschlies KL, Ortaldo JR, Sayers TJ, Wiltrout RH, Longo DL.
Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
J. Clin. Invest. 92: 1918-24, 1993.
103)  Forough R, Xi Z, MacPhee M, Friedman S, Engleka KA, Sayers T, Wiltrout RH, Maciag T.
Differential transforming abilities of non-secreted and secreted forms of human fibroblast growth factor-1.
J. Biol. Chem. 268: 2960-8, 1993.
104)  Murphy WJ, Conlon KC, Sayers TJ, Wiltrout RH, Back TC, Ortaldo JR, Longo DL.
Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
J. Immunol. 150: 3634-42, 1993.
105)  Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E.
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Cancer Res. 53: 5613-6, 1993.
106)  Pearson JW, Fogler WE, Volker K, Riggs CW, Gruys E, Groves ES, Wiltrout RH, Longo DL.
Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
J. Natl. Cancer Inst. 85: 907-12, 1993.
107)  Sayers TJ, Mason LH, Pilaro A, Wiltrout TA, Komschlies K, Munger WL, Wiltrout RH.
Substrate-specific proteases (BLT-esterase) are localized predominantly in the natural killer cells of unprimed mice.
J. Leukoc. Biol. 53: 454-61, 1993.
108)  Damia G, Komschlies KL, Faltynek CR, Ruscetti FW, Wiltrout RH.
Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice.
Blood. 79: 1121-9, 1992.
109)  Futami H, Eader L, Back TT, Gruys E, Young HA, Wiltrout RH, Baguley BC.
Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives.
J. Immunother. 12: 247-55, 1992.
110)  Ayroldi E, Blasi E, Varesio L, Wiltrout RH.
Inhibition of proliferation of retrovirus-immortalized macrophages by LPS and IFN-gamma: possible autocrine down-regulation of cell growth by induction of IL1 and TNF.
Biotherapy. 4: 267-76, 1992.
111)  Damia G, Komschlies KL, Futami H, Back T, Gruys ME, Longo DL, Keller JR, Ruscetti FW, Wiltrout RH.
Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.
Cancer Res. 52: 4082-9, 1992.
112)  Jansen R, Damia G, Usui N, Keller J, Futami H, Goey H, Back TT, Longo DL, Ruscetti FW, Wiltrout RH.
Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil.
J. Immunol. 147: 3342-7, 1991.
113)  Futami H, Eader LA, Komschlies KL, Bull R, Gruys ME, Ortaldo JR, Young HA, Wiltrout RH.
Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes.
Cancer Res. 51: 6596-602, 1991.
114)  Ruscetti FW, Dubois C, Falk LA, Jacobsen SE, Sing G, Longo DL, Wiltrout RH, Keller JR.
In vivo and in vitro effects of TGF-beta 1 on normal and neoplastic haemopoiesis.
Ciba Found. Symp. 157: 212-27; discussion 227-31, 1991.
115)  Futami H, Pilaro AM, Gruys ME, Back TC, Young HA, Wiltrout RH.
In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells.
Biotherapy. 3: 219-32, 1991.
116)  Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T.
Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.
J. Natl. Cancer Inst. 83: 1386-91, 1991.
117)  Pilaro AM, Sayers TJ, McCormick KL, Reynolds CW, Wiltrout RH.
An improved in vitro assay to quantitate chemotaxis of rat peripheral blood large granular lymphocytes (LGL).
J. Immunol. Methods. 135: 213-23, 1990.
118)  Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH.
Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Cancer Res. 50: 5414-20, 1990.
119)  Futami H, Jansen R, MacPhee MJ, Keller J, McCormick K, Longo DL, Oppenheim JJ, Ruscetti FW, Wiltrout RH.
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
J. Immunol. 145: 4121-30, 1990.
120)  Mace KF, Hornung RL, Wiltrout RH, Young HA.
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer.
Cancer Res. 50: 1742-7, 1990.
121)  Pearson JW, Hedrick E, Fogler WE, Bull RL, Ferris DK, Riggs CW, Wiltrout RH, Sivam G, Morgan AC, Groves E.
Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
Cancer Res. 50: 6379-88, 1990.
122)  Ortaldo JR, Wiltrout RH.
Implications of potential positive correlation between autologous tumor-cell-killing activity and prognosis in lung cancer.
J. Natl. Cancer Inst. 82: 1663-5, 1990.
123)  Futami H, Hornung RL, Back TT, Bull R, Gruys E, Wiltrout RH.
Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
Cancer Res. 50: 7926-31, 1990.
124)  Rees RC, Wiltrout RH.
The biology and clinical applications of interleukin 2.
Immunol. Today. 11: 36-8, 1990.
125)  Wiltrout RH, Pilaro AM, Gruys ME, Talmadge JE, Longo DL, Ortaldo JR, Reynolds CW.
Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
J. Immunol. 143: 372-8, 1989.
126)  Pearson JW, FitzGerald DJ, Willingham MC, Wiltrout RH, Pastan I, Longo DL.
Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice.
Cancer Res. 49: 3562-7, 1989.
127)  Pearson JW, Sivam G, Manger R, Wiltrout RH, Morgan AC, Longo DL.
Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice.
Cancer Res. 49: 4990-5, 1989.
128)  Goey H, Keller JR, Back T, Longo DL, Ruscetti FW, Wiltrout RH.
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1.
J. Immunol. 143: 877-80, 1989.
129)  Wiltrout RH, Salup RR.
Adoptive immunotherapy in combination with chemotherapy for cancer treatment.
Prog Exp Tumor Res. 32: 128-53, 1988.
130)  Hornung RL, Back TC, Zaharko DS, Urba WJ, Longo DL, Wiltrout RH.
Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
J. Immunol. 141: 3671-9, 1988.
131)  Ortaldo JR, Mathieson BJ, Wiltrout RH.
Characterization and functions of natural killer cells.
Ann. Inst. Pasteur Immunol. 139: 444-50, 1988.
132)  Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Hornung RL.
Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
J. Immunol. 140: 3261-5, 1988.
133)  Hornung RL, Young HA, Urba WJ, Wiltrout RH.
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta.
J. Natl. Cancer Inst. 80: 1226-31, 1988.
134)  Wiltrout RH, Hornung RL.
Natural products as antitumor agents: direct versus indirect mechanisms of activity of flavonoids.
J. Natl. Cancer Inst. 80: 220-2, 1988.
135)  Blasi E, Varesio L, Wiltrout RH.
Tumor formation by a murine macrophage cell line immortalized in vitro by v-raf and v-myc oncogenes.
Cancer Immunol. Immunother. 27: 109-13, 1988.
136)  Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH.
Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
Cancer Res. 47: 2563-70, 1987.
137)  Twilley TA, Mason L, Talmadge JE, Wiltrout RH.
Increase in liver-associated natural killer activity by polyribonucleotides.
Nat. Immun. Cell Growth Regul. 6: 279-90, 1987.
138)  Salup RR, Mathieson BJ, Wiltrout RH.
Precursor phenotype of lymphokine-activated killer cells in the mouse.
J. Immunol. 138: 3635-9, 1987.
139)  Salup RR, Back TC, Wiltrout RH.
Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.
J. Immunol. 138: 641-7, 1987.
140)  Wiltrout RH, Mathieson BJ, Back TC, Salup RR.
Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy.
Prog. Clin. Biol. Res. 244: 17-25, 1987.
141)  Salup RR, Wiltrout RH.
Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
Cancer Res. 46: 3358-63, 1986.
142)  Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB, Wiltrout RH.
Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2.
Cancer Immunol. Immunother. 21: 19-25, 1986.
143)  Wiltrout RH, Denn AC, Reynolds CW.
Augmentation of organ-associated NK activity by BRMs: association of NK activity with mononuclear cell infiltration.
Pathol Immunopathol Res. 5: 219-33, 1986.
144)  Talmadge JE, Wiltrout RH, Counts DF, Herberman RB, McDonald T, Ortaldo JR.
Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes.
Cell. Immunol. 102: 261-72, 1986.
145)  Salup RR, Wiltrout RH.
Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.
Cancer Immunol. Immunother. 22: 31-6, 1986.
146)  Talmadge JE, Schneider M, Collins M, Phillips H, Herberman RB, Wiltrout RH.
Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
J. Immunol. 135: 1477-83, 1985.
147)  Santoni A, Piccoli M, Ortaldo JR, Mason L, Wiltrout RH, Herberman RB.
Changes in number and density of large granular lymphocytes upon in vivo augmentation of mouse natural killer activity.
J. Immunol. 134: 2799-810, 1985.
148)  Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW.
Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.
J. Immunol. 134: 2783-9, 1985.
149)  Kleinerman ES, Wiltrout RH, Zicht R, Fidler IJ.
Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.
Cancer Immunol. Immunother. 20: 151-7, 1985.
150)  Wiltrout RH, Salup RR, Twilley TA, Talmadge JE.
Immunomodulation of natural killer activity by polyribonucleotides.
J Biol Response Mod. 4: 512-7, 1985.
151)  Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Schlick E, Ruffmann R, Wiltrout RH, Chirigos MA.
Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
Cancer Res. 45: 1058-65, 1985.
152)  Gorelik E, Wiltrout RH, Brunda MJ, Bere WE, Herberman RB.
Influence of adoptively transferred thioglycollate-elicited peritoneal macrophages on metastasis formation in mice with depressed or stimulated NK activity.
Clin. Exp. Metastasis. 3: 111-23, 1985.
153)  Gorelik E, Wiltrout RH, Copeland D, Herberman RB.
Modulation of formation of tumor metastases by peritoneal macrophages elicited by various agents.
Cancer Immunol. Immunother. 19: 35-42, 1985.
154)  Wiltrout RH, Santoni A, Peterson ES, Knott DC, Overton WR, Herberman RB, Holden HT.
Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages.
J. Leukoc. Biol. 37: 597-614, 1985.
155)  Salup RR, Herberman RB, Wiltrout RH.
Role of natural killer activity in development of spontaneous metastases in murine renal cancer.
J. Urol. 134: 1236-41, 1985.
156)  Wiltrout RH, Herberman RB, Zhang SR, Chirigos MA, Ortaldo JR, Green KM, Talmadge JE.
Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.
J. Immunol. 134: 4267-75, 1985.
157)  Salup RR, Herberman RB, Chirigos MA, Back T, Wiltrout RH.
Therapy of peritoneal murine cancer with biological response modifiers.
J Immunopharmacol. 7: 417-36, 1985.
158)  Nestel FP, Casson PR, Wiltrout RH, Kerbel RS.
Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants.
J. Natl. Cancer Inst. 73: 483-91, 1984.
159)  Wiltrout RH, Mathieson BJ, Talmadge JE, Reynolds CW, Zhang SR, Herberman RB, Ortaldo JR.
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver.
J. Exp. Med. 160: 1431-49, 1984.
160)  Talmadge JE, Maluish AE, Collins M, Schneider M, Herberman RB, Oldham RK, Wiltrout RH.
Immunomodulation and antitumor effects of MVE-2 in mice.
J Biol Response Mod. 3: 634-52, 1984.
161)  Reynolds CW, Denn AC, Barlozzari T, Wiltrout RH, Reichardt DA, Herberman RB.
Natural killer activity in the rat. IV. Distribution of large granular lymphocytes (LGL) following intravenous and intraperitoneal transfer.
Cell. Immunol. 86: 371-80, 1984.
162)  Varesio L, Blasi E, Thurman GB, Talmadge JE, Wiltrout RH, Herberman RB.
Potent activation of mouse macrophages by recombinant interferon-gamma.
Cancer Res. 44: 4465-9, 1984.
163)  Wiltrout RH, Gorelik E, Brunda MJ, Holden HT, Herberman RB.
Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.
Cancer Immunol. Immunother. 14: 172-9, 1983.
164)  Wiltrout RH, Brunda MJ, Gorelik E, Peterson ES, Dunn JJ, Leonhardt J, Varesio L, Reynolds CW, Holden HT.
Distribution of peritoneal macrophage populations after intravenous injection in mice: differential effects of eliciting and activating agents.
J Reticuloendothel Soc. 34: 253-69, 1983.
165)  Brunda MJ, Wiltrout RH, Holden HT, Varesio L.
Selective inhibition by monosaccharides of tumor cell cytotoxicity mediated by mouse macrophages, macrophage-like cell lines, and natural killer cells.
Int. J. Cancer. 31: 373-9, 1983.
166)  Gorelik E, Wiltrout RH, Brunda MJ, Holden HT, Herberman RB.
Augmentation of metastasis formation by thioglycollate-elicited macrophages.
Int. J. Cancer. 29: 575-81, 1982.
167)  Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB.
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.
Int. J. Cancer. 30: 107-12, 1982.
168)  Wiltrout RH, Brunda MJ, Holden HT.
Variation in selectivity of tumor cell cytolysis by murine macrophages, macrophage-like cell lines and NK cells.
Int. J. Cancer. 30: 335-42, 1982.
169)  Wiltrout RH, Taramelli D, Holden HT.
Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 11 indium-oxine.
J. Immunol. Methods. 43: 319-31, 1981.
170)  Wiltrout RH, Frost P.
Cell-mediated cytotoxic responses induced in vivo and in vitro by a metastatic murine tumor.
J. Immunol. 124: 2254-63, 1980.
171)  Wiltrout RH, Frost P, Morrison MK.
Immune regression of visceral metastases in athymic mice. Correlation of.
Transplantation. 29: 283-86, 1980.
172)  Wiltrout RH, Frost P, Morrison MK, Kerbel RS.
Immune-mediated arrest and reversal of established visceral metastases in athymic mice.
Cancer Res. 39: 4034-41, 1979.
173)  Wiltrout RH, Frost P, Cummings GD.
Isotope-release cytotoxicity assay with the use of indium-111: advantage over chromium-51 in long-term assays.
J. Natl. Cancer Inst. 61: 183-8, 1978.
174)  Frost P, Wiltrout R, Maciorowski Z, Rose NR.
An isotope release cytotoxicity assay applicable to human tumors: the use of 111indium.
Oncology. 34: 102-4, 1977.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/14/2014.